Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis

We deleted the hypoxia-responsive transcription factor HIF-1alpha in endothelial cells (EC) to determine its role during neovascularization. We found that loss of HIF-1alpha inhibits a number of important parameters of EC behavior during angiogenesis: these include proliferation, chemotaxis, extracellular matrix penetration, and wound healing. Most strikingly, loss of HIF-1alpha in EC results in a profound inhibition of blood vessel growth in solid tumors. These phenomena are all linked to a decreased level of VEGF expression and loss of autocrine response of VEGFR-2 in HIF-1alpha null EC. We thus show that a HIF-1alpha-driven, VEGF-mediated autocrine loop in EC is an essential component of solid tumor angiogenesis.

[1]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[2]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[3]  J. Folkman,et al.  Fighting cancer by attacking its blood supply. , 1996, Scientific American.

[4]  Y Fujii-Kuriyama,et al.  A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Hammer,et al.  Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. , 2001, Developmental biology.

[6]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[7]  R K Jain,et al.  Growth factors: Formation of endothelial cell networks , 2000, Nature.

[8]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[9]  W. Risau,et al.  HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1α and developmentally expressed in blood vessels , 1997, Mechanisms of Development.

[10]  D. Hanahan,et al.  Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. , 1996, European journal of cancer.

[11]  S. McKnight,et al.  Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. , 1997, Genes & development.

[12]  J. Schrader,et al.  Energy turnover of vascular endothelial cells. , 1997, The American journal of physiology.

[13]  A. Singer,et al.  Cutaneous wound healing. , 1999, The New England journal of medicine.

[14]  A. Giaccia,et al.  Hypoxia-Induced Gene Expression Occurs Solely through the Action of Hypoxia-Inducible Factor 1α (HIF-1α): Role of Cytoplasmic Trapping of HIF-2α , 2003, Molecular and Cellular Biology.

[15]  V. V. van Hinsbergh,et al.  Hypoxia in combination with FGF-2 induces tube formation by human microvascular endothelial cells in a fibrin matrix: involvement of at least two signal transduction pathways. , 2001, Journal of cell science.

[16]  A. Passaniti,et al.  A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[17]  Jie Li,et al.  Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix , 2003, Microscopy research and technique.

[18]  J. Arbeit,et al.  c-Jun is essential for organization of the epidermal leading edge. , 2003, Developmental cell.

[19]  J. Peng,et al.  Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. , 1999, Development.

[20]  N. Ferrara,et al.  The Role of Vascular Endothelial Growth Factor in Angiogenesis , 2002, Acta Haematologica.

[21]  T. Noda,et al.  Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. , 2001, Cancer research.

[22]  B. Keyt,et al.  Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro * , 1998, The Journal of Biological Chemistry.

[23]  N. Ferrara,et al.  Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) , 2001, The Journal of Biological Chemistry.

[24]  C. Garlanda,et al.  A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[25]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[26]  Atsushi Namiki,et al.  Indirect Angiogenic Cytokines Upregulate VEGF and bFGF Gene Expression in Vascular Smooth Muscle Cells, Whereas Hypoxia Upregulates VEGF Expression Only , 1994 .

[27]  Kan Ding,et al.  Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1−/− mice , 2003, Nature Genetics.

[28]  VinzenzHombach,et al.  Functional Upregulation of the Vascular Endothelial Growth Factor Receptor KDR by Hypoxia , 1996 .

[29]  P. Thibault,et al.  Transcription Factor HIF-1 Is a Necessary Mediator of the Pasteur Effect in Mammalian Cells , 2001, Molecular and Cellular Biology.

[30]  K. Alitalo,et al.  Vascular growth factors and lymphangiogenesis. , 2002, Physiological reviews.

[31]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[32]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[33]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 , 1998 .

[34]  Tarik Tihan,et al.  The hypoxic response of tumors is dependent on their microenvironment. , 2003, Cancer cell.

[35]  Bryan Welm,et al.  HIF1alpha is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. , 2003, Development.

[36]  Christopher A Bradfield,et al.  Expression of ARNT, ARNT2, HIF1α, HIF2α and Ah receptor mRNAs in the developing mouse , 1998, Mechanisms of Development.

[37]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[38]  J. Remacle,et al.  Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. , 2000, Biochimica et biophysica acta.

[39]  T. K. Hunt,et al.  Regulation of wound-healing angiogenesis-effect of oxygen gradients and inspired oxygen concentration. , 1981, Surgery.

[40]  A. Giaccia,et al.  Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. , 2003, Molecular and cellular biology.

[41]  S. Rafii,et al.  Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. , 2003, Trends in molecular medicine.

[42]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[43]  D. Pinsky,et al.  Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction , 2002, Current opinion in critical care.

[44]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[45]  G. Semenza.  Hypoxia-Inducible Factor 1: Control of Oxygen Homeostasis in Health and Disease , 2001, Pediatric Research.

[46]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[47]  Napoleone Ferrara,et al.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.

[48]  P. Phillips,et al.  Hypoxia induces capillary network formation in cultured bovine pulmonary microvessel endothelial cells. , 1995, The American journal of physiology.

[49]  A. Harris,et al.  Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. , 2003, Cancer research.

[50]  Margaret C. Neville,et al.  HIF1α is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland , 2003 .

[51]  J. M. Arbeit,et al.  Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. , 2000, Cancer research.

[52]  John R Griffiths,et al.  Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. , 2002, Cancer research.

[53]  S. Jain,et al.  Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. , 1998, Mechanisms of development.

[54]  Elisabetta Dejana,et al.  The conditional inactivation of the β-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility , 2003, The Journal of cell biology.

[55]  R. Clark,et al.  Mesenchymal cell activation is the rate-limiting step of granulation tissue induction. , 1996, The American journal of pathology.

[56]  V. Hombach,et al.  Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. , 1996, Circulation.

[57]  H. Ryan,et al.  HIF-1 alpha is required for solid tumor formation and embryonic vascularization. , 1998, The EMBO journal.

[58]  Rainer Constien,et al.  Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line , 2001, Genesis.

[59]  Brian Keith,et al.  Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.

[60]  H. Farber,et al.  Endothelial cell tolerance to hypoxia. Potential role of purine nucleotide phosphates. , 1995, The Journal of clinical investigation.

[61]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[62]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[63]  A. Harris,et al.  Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis , 1995, The Journal of pathology.

[64]  Xiaodong Feng,et al.  Angiogenesis in wound healing. , 2000, The journal of investigative dermatology. Symposium proceedings.

[65]  N. Voelkel,et al.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. , 1995, The Journal of clinical investigation.

[66]  M. Shibuya.  Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). , 2001, The international journal of biochemistry & cell biology.

[67]  F. M. Gabhann,et al.  receptors on endothelial cells growth factor and placental growth factor to VEGF Model of competitive binding of vascular endothelial , 2005 .

[68]  J. Folkman.  Tumor angiogenesis and tissue factor , 1996, Nature Medicine.